ACTU (Actuate Therapeutics) Total Operating Expense: $21.84 Mil (TTM As of Mar. 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.82
View Full Analysis

What is Actuate Therapeutics Total Operating Expense?

Actuate Therapeutics ACTU -14.29% 14 Total Operating Expense is $21.84 Mil as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $5.71 Mil. Actuate Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $21.84 Mil.

Actuate Therapeutics Total Operating Expense Related Terms

Actuate Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Total Operating Expense Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
20.21 24.97 25.16 22.50

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.37 5.97 5.47 4.69 5.71
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $21.84 Mil mean?
Actuate Therapeutics (ACTU) has a Total Operating Expense of $21.84 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Total Operating Expense too high?
Actuate Therapeutics' current Total Operating Expense is $21.84 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Total Operating Expense compare to AURX and ESLA?
Actuate Therapeutics' Total Operating Expense of $21.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Total Operating Expense is $21.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Total Operating Expense of $21.84 Mil. The current Total Operating Expense is $21.84 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Total Operating Expense is $21.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price